STAT May 28, 2024
LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.
The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended...